RxDoctor Payments Data

Troy Davison

Physician Assistant · Kingman, AZNPI 1114023595

Payments from drug & device makers

$879in general payments, 2019–2025

Across 35 payments — averaging $25.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$168
  • Bayer$139
  • Astellas Pharma US Inc$134
  • Amgen$82
  • AstraZeneca$78
  • Corcept Therapeutics$57
  • plus $222 from 9 others

What the payments were for

  • Food & beverage$77989%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$879 in reported general payments places this provider in the 65th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$28,947
Medicare patients
95
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter124$96,208
JardianceEmpagliflozin100$86,953
JanuviaSitagliptin Phosphate44$60,285
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$54,943
EliquisApixaban77$52,223
Humalog Kwikpen U-200Insulin Lispro11$42,795
OzempicSemaglutide23$28,055
MyrbetriqMirabegron43$25,930
Atrovent HfaIpratropium Bromide45$25,439
FarxigaDapagliflozin Propanediol29$20,075
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$19,608
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$17,110
TradjentaLinagliptin16$13,906
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,809
Breo ElliptaFluticasone/Vilanterol25$9,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$40$105,960149 claims
PfizerEliquis$33$52,22377 claims
Astellas Pharma US IncMyrbetriq$134$25,93043 claims
AstraZenecaFarxiga$78$20,07529 claims
NovartisEntresto$13$8,75612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Kingman

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →